Navigation Links
Actinium Pharmaceuticals Appoints Corey Sohmer As Vice President Of Finance And Business Development
Date:9/18/2013

NEW YORK, Sept. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Corey Sohmer to the position of Vice President of Finance and Business Development.  Mr. Sohmer will be responsible for directing Actinium's accounting, finance and investor relations functions as well as supporting capital raising and business development activities.

"Corey has a broad financial background in the biotech industry. He brings leadership experience relevant to all key aspects of Actinium's corporate development, including financing, accounting, investor relations and public reporting," said Kaushik J. Dave, Ph.D., MBA, President and CEO of Actinium.  "Corey will be an extremely valuable addition to the Actinium team as we continue to progress the Company's lead candidates Iomab-B and Actimab-A."

"I am excited to join the Company at a pivotal point in its growth and look forward to contributing to its future success," said Mr. Sohmer.  Prior to joining Actinium, Mr. Sohmer served in a variety of core finance and business development functions over the span of twelve years at three NASDAQ listed biopharmaceutical companies.  Most recently, Mr. Sohmer was the Director Corporate Finance at Cyclacel Pharmaceuticals, Inc. for six years.   Before joining Cyclacel, he was the Senior Director of Financial Planning and External Reporting at EpiCept Corporation and Manager of Finance and Business Development at Pharmos Corporation.  He has more than 20 years of finance and accounting experience.  Mr. Sohmer holds a Masters in Business Administration and a Bachelors of Science degree in Accounting from Bentley University.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:
Visit our web site www.actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr.
Tel:  (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com

Contact:
Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
E-mail: ir@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
2. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
3. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
4. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
5. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
7. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
8. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
9. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
10. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
11. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary   ... Medical cannabis products around the ... Inc., projects that the global medical cannabis market will reach a value ... is a major market for the new growing industry. By the end ... legally buy and sell medical cannabis. More conservative states like ...
(Date:3/24/2017)... 24, 2017 A ReportsnReports.com report says, over ... rapidly as the global sales of Adcetris and Kadcyla have been ... antibody drug conjugates market is driven by large number of ADC ... therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , Latin America ... for the period 2015 through 2022. Also, a six-year historic analysis is ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... “Finding Christ Through Social Media: Year One #A365DayJourney to ... path toward true communion with God. “Finding Christ Through Social Media: Year One ... published author Lea Michelle Johnson, a follower of Christ, wife and mother who ...
(Date:3/24/2017)... ... , ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a ... to the fullest, as God intended. “The Adventures of Joey, The Dog Who Barks ... pursuing her passion for writing, especially about truth and human behavior. , Published by ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... to their communities, 16 more public health departments have been awarded national accreditation ... another 4.5 million people into the expanding network of communities across the nation ...
(Date:3/23/2017)... ... 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of those whose careers ... impact on the careers of all others involved. , On Monday, March 21st, ... MBI’s Hall of Fame. The induction took place during the World of Modular – ...
(Date:3/23/2017)... Atlanta, GA (PRWEB) , ... March 23, 2017 ... ... announced the release of SmartBen NOW, an innovative mobile app and centralized benefits ... gather and present critical information securely from multiple locations. For the first time, ...
Breaking Medicine News(10 mins):